Figure 1
From: Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1+CD8 T cells
Allogeneic dendritic cells could elicit efficient antitumor effects. (a) Schematic diagram of the investigation of antitumor effects by allogeneic immunocytes. (b,c) B6 mice were pre-immunized with 108 or 107 of splenocytes from DBA/2 mice (▲) or B6 mice (●), respectively. After immunization for two times, they were inoculated subcutaneously with 2 × 106 EL4 cells. EL4 tumor sizes were detected at indicated time points. (d-f) 5 × 107 TCRβ−CD19+B cells (d), 1 × 106 TCRβ−CD19−CD11c+Ia+dendritic cells (e) and 3 × 107 TCRβ+CD19−T cells (f) were isolated from splenocytes of DBA/2 (▲) or B6 (●) mice by flow cytometry and injected intraperitoneally into recipient B6 mice for two times. Recipient mice were inoculated subcutaneously with 2 × 106 EL4 cells. EL4 tumor sizes were detected at indicated time points. (g–i) B6 mice were pre-immunized intraperitoneally by 1 × 106 DBA DC (▲) or B6 DC (●) for two times. Then mice were inoculated subcutaneously with 1 × 106 S180 cells (g) or 1 × 106 H22 cells (h), or injected intravenously with 5 × 105 B16 cells (i), and tumor growth were monitored. (j–l) DCs from FVB mice (▲) or B6 mice (●) were immunized into B6 mice for two times. Then recipient mice were inoculated subcutaneously with 2 × 106 EL4 cells (j), 1 × 106 H22 cells (k) or 1 × 106 S180 cells. (l) Tumor sizes were recorded at indicated time points. Recipient mice injected with PBS (■) were used as the blank control. These experiments were repeated for 3 times. n = 5 for each repeat. P values indicated the statistical significance when comparing with blank control group (ip PBS group).
